Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1-3.

Liu S, Gong Y, Ren H, Zhang W, Chen X, Zhou T, Li X, Chen N.

Oncotarget. 2017 Jul 6;8(34):57099-57108. doi: 10.18632/oncotarget.19051. eCollection 2017 Aug 22.

PMID:
28915657
2.
3.

JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.

Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, Miyashita T, Suzuki S, Morimoto S, Tamura N, Takamori K, Ogawa H, Sekigawa I.

BMC Immunol. 2017 Aug 22;18(1):41. doi: 10.1186/s12865-017-0225-9.

4.

Apoptosis inhibitor of macrophage ameliorates fungus-induced peritoneal injury model in mice.

Tomita T, Arai S, Kitada K, Mizuno M, Suzuki Y, Sakata F, Nakano D, Hiramoto E, Takei Y, Maruyama S, Nishiyama A, Matsuo S, Miyazaki T, Ito Y.

Sci Rep. 2017 Jul 25;7(1):6450. doi: 10.1038/s41598-017-06824-6.

5.

MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus.

Leiss H, Salzberger W, Jacobs B, Gessl I, Kozakowski N, Blüml S, Puchner A, Kiss A, Podesser BK, Smolen JS, Stummvoll GH.

PLoS One. 2017 Jul 18;12(7):e0181015. doi: 10.1371/journal.pone.0181015. eCollection 2017.

6.

Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis.

Yung S, Yap DY, Chan TM.

F1000Res. 2017 Jun 13;6:874. doi: 10.12688/f1000research.10445.1. eCollection 2017. Review.

7.

Current status of lupus nephritis.

Jaryal A, Vikrant S.

Indian J Med Res. 2017 Feb;145(2):167-178. doi: 10.4103/ijmr.IJMR_163_16. Review.

8.

Anti-Double-Stranded DNA IgG Participates in Renal Fibrosis through Suppressing the Suppressor of Cytokine Signaling 1 Signals.

Wang P, Yang J, Tong F, Duan Z, Liu X, Xia L, Li K, Xia Y.

Front Immunol. 2017 May 31;8:610. doi: 10.3389/fimmu.2017.00610. eCollection 2017.

9.

The value of repeat biopsy in lupus nephritis flares.

Narváez J, Ricse M, Gomà M, Mitjavila F, Fulladosa X, Capdevila O, Torras J, Juanola X, Pujol-Farriols R, Nolla JM.

Medicine (Baltimore). 2017 Jun;96(24):e7099. doi: 10.1097/MD.0000000000007099. Review.

10.

High-sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematous patients: a cross-sectional controlled study.

Divard G, Abbas R, Chenevier-Gobeaux C, Chanson N, Escoubet B, Chauveheid MP, Dossier A, Papo T, Dehoux M, Sacre K.

Arthritis Res Ther. 2017 Jun 13;19(1):132. doi: 10.1186/s13075-017-1352-7.

11.

MMP2 and MMP9 associate with crescentic glomerulonephritis.

Phillips TM, Fadia M, Lea-Henry TN, Smiles J, Walters GD, Jiang SH.

Clin Kidney J. 2017 Apr;10(2):215-220. doi: 10.1093/ckj/sfw111. Epub 2016 Dec 26.

12.

Digital pathology imaging as a novel platform for standardization and globalization of quantitative nephropathology.

Barisoni L, Gimpel C, Kain R, Laurinavicius A, Bueno G, Zeng C, Liu Z, Schaefer F, Kretzler M, Holzman LB, Hewitt SM.

Clin Kidney J. 2017 Apr;10(2):176-187. doi: 10.1093/ckj/sfw129. Epub 2017 Feb 18.

13.

Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury.

Tato M, Kumar SV, Liu Y, Mulay SR, Moll S, Popper B, Eberhard JN, Thomasova D, Rufer AC, Gruner S, Haap W, Hartmann G, Anders HJ.

Sci Rep. 2017 Jun 5;7(1):2775. doi: 10.1038/s41598-017-01894-y.

14.

The Increased Expression of Toll-Like Receptor 4 in Renal and Skin Lesions in Lupus Erythematosus.

Elloumi N, Fakhfakh R, Ayadi L, Sellami K, Abida O, Ben Jmaa M, Sellami T, Kammoun K, Masmoudi H.

J Histochem Cytochem. 2017 Jul;65(7):389-398. doi: 10.1369/0022155417709234. Epub 2017 May 22.

PMID:
28530841
15.

Lupus nephritis class I accompanied by tubulointerstitial nephritis with marked T-lymphocyte infiltration in an HTLV-1 positive patient.

Imasawa T, Kitamura H, Nishimura M, Kawaguchi T, Takata K, Yoshino T, Sugisaki Y.

CEN Case Rep. 2013 May;2(1):90-97. doi: 10.1007/s13730-012-0044-z. Epub 2012 Nov 3.

16.

Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity.

Westerterp M, Gautier EL, Ganda A, Molusky MM, Wang W, Fotakis P, Wang N, Randolph GJ, D'Agati VD, Yvan-Charvet L, Tall AR.

Cell Metab. 2017 Jun 6;25(6):1294-1304.e6. doi: 10.1016/j.cmet.2017.04.005. Epub 2017 May 4.

PMID:
28479366
17.

Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.

Der E, Ranabothu S, Suryawanshi H, Akat KM, Clancy R, Morozov P, Kustagi M, Czuppa M, Izmirly P, Belmont HM, Wang T, Jordan N, Bornkamp N, Nwaukoni J, Martinez J, Goilav B, Buyon JP, Tuschl T, Putterman C.

JCI Insight. 2017 May 4;2(9). pii: 93009. doi: 10.1172/jci.insight.93009. [Epub ahead of print]

18.

Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls.

Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, Pettersson S, Elvin K, Öhrvik J, Larsson A, Jensen-Urstad K, Svenungsson E.

PLoS One. 2017 Apr 17;12(4):e0174572. doi: 10.1371/journal.pone.0174572. eCollection 2017.

19.

Surface complement C3 fragments and cellular binding of microparticles in patients with SLE.

Winberg LK, Nielsen CH, Jacobsen S.

Lupus Sci Med. 2017 Mar 31;4(1):e000193. doi: 10.1136/lupus-2016-000193. eCollection 2017.

20.

A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus.

Nielsen CT, Østergaard O, Rasmussen NS, Jacobsen S, Heegaard NHH.

Clin Proteomics. 2017 Apr 8;14:11. doi: 10.1186/s12014-017-9146-0. eCollection 2017. Review.

Supplemental Content

Support Center